Topical Amphotericin B for Cutaneous Leishmaniasis

Vardy, Daniel; Barenholz, Yechezkel; Cohen, Rivka; Zvulunov, Alex; Biton, Amnon; Klaus, Sidney N.; Frankenburg, Shoshana

doi:10.1001/archderm.135.7.856

Cited by 26 publications

(25 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zvulunov et al even reported successful treatment of a 1.5-year-old infant with persistent CL by the administration of a topical colloidal solution of AmB for 3 weeks [21]. In a study conducted in 1999 on the treatment outcome of two similar lesions of the same individual, the topical liposomal AmB-treated lesions showed significant improvement with no evidence of relapse when compared to the placebo-treated ones [9]. Another study taking place in Israel on 19 patients receiving 2 vials, one containing AmB-cholesteryl sulfate dispersed in a 5% ethanol solution and one with 5% ethanol in water for half of each patient's lesions, the results revealed a better therapeutic response in those lesions treated with topical liposomal AmB in comparison to placebo [22].…”

Section: Discussionmentioning

confidence: 99%

“…The possible transdermal passages of AmB into blood circulation were previously ruled out [9]. The apparent volume of distribution of liposomal form of AmB is reported to be 0.1–0.44 lit/kg while the maximum therapeutic concentration of this drug is about 1–1.5 mg/kg [13].…”

Section: Methodsmentioning

confidence: 99%

“…In a mouse model it has been shown that topical AmB as a complex either with cholesteryl sulfate or with phospholipids in the presence of ethanol can penetrate into the skin and cure CL in a localized manner using a very low total drug concentration [8]. In another study topical AmB was proven to be effective against CL caused by Leishmania major [9]. Since liposomal AmB is administered topically, it could be considered as a good alternative in the treatment of CL.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis

Layegh

Rajabi

Jafari

et al. 2011

Journal of Parasitology Research

View full text Add to dashboard Cite

Background. Topical treatment of cutaneous leishmaniasis is an attractive alternative avoiding toxicities of parenteral therapy while being administered through a simple painless route. Recently liposomal formulations of amphotericin B have been increasingly used in the treatment of several types of leishmaniasis. Aims. The efficacy of a topical liposomal amphotericin B formulation was compared with intralesional glucantime in the treatment of cutaneous leishmaniasis. Methods. From 110 patients, the randomly selected 50 received a topical liposomal formulation of amphotericin B into each lesion, 3–7 drops twice daily, according to the lesion's size and for 8 weeks. The other group of 60 patients received intralesional glucantime injection of 1-2 mL once a week for the same period. The clinical responses and side effects of both groups were evaluated weekly during the treatment course. Results. Per-protocol analysis showed no statistically significant difference between the two groups (P = 0.317, 95% confidence interval (CI) = 1.610 (0.632–4.101)). Moreover, after intention-to-treat analysis, the same results were seen (P = 0.650, 95% CI = 0.1.91 (0.560–2.530)). Serious post treatment side effects were not observed in either group. Conclusions. Topical liposomal amphotericin B has the same efficacy as intralesional glucantime in the treatment of cutaneous leishmaniasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis

Layegh

Rajabi

Jafari

et al. 2011

Journal of Parasitology Research

View full text Add to dashboard Cite

show abstract

“…Miltefosine is recommended for New World cutaneous disease to diminish the time to cure the ulcer and to attempt to prevent metastasis . It is an oral agent administered at a dose of 2.5 mg/kg/d for approximately 28 days, and with very few side effects such as nausea, vomiting, and mild elevation of serum creatinine; relapses have been described in cases of anergic diffuse cutaneous leishmaniasis .…”

Section: Treatmentmentioning

confidence: 99%

American cutaneous leishmaniasis in infancy and childhood

et al. 2017

View full text Add to dashboard Cite

Infant and young child skin diseases are among the most common features of morbidity throughout the tropics. Because the skin is directly exposed to the environment, it is considerably affected by climatic and local conditions such as vectors and microorganisms, as in the case of leishmaniasis. In America the observed magnitude of cutaneous leishmaniasis in children has led to the study of increased risk of exposure of this group due to the possibility of peri- and intradomiciliary transmission. The present review pretends to make a concrete approach all through the broad and main figures of this parasitic disease, including the clinical, physiopathological, epidemiological, diagnostic, and therapeutic aspects, in order to be used as a practical source of reference for pediatricians leading with tropical cutaneous pathology in the region.

show abstract

“…Quinacrine, miconazole, clotrimazole, chlorpromazine, amphotericin, garlic cream and ZHE cream are some of these medications in treatment of cutaneous leishmaniasis lesions. [121314151617]…”

Section: Discussionmentioning

confidence: 99%

The efficacy of Achilles millefolium topical gel along with intralesional injection of glucantime in the treatment of acute cutaneous leishmaniasis major

et al. 2014

View full text Add to dashboard Cite

Background:Leishmaniasis is still one of the endemic parasitic infections in many countries comprising Iran. During the past decades, several medical and surgical approaches have been applied and studied to achieve the best option to treat the cutaneous leishmaniasis in Iran and the world. This study was carried out to evaluate the effect of topical Achilles millefolium in conjunction with intralesional glucantime on acute cutaneous leishmanial lesions.Materials and Methods:sixty patients with confirmed acute cutaneous leishmaniasis were recruited in the study. Patients were randomly allocated into two groups to receive twice daily topical gel of Achilles millefolium 5% (containing 5% poly phenol) (group A) or placebo (group B) for four weeks along with weekly injection of intralesional Glucantime.Results:There was no significant difference between the two groups according to age, gender, and duration of the disease. Also, there was no significant difference in complete and relative cure rates between the two groups (P = 0.35) using Visual Analog Scale (VAS). Application site reactions were occurred in 12 patients including redness in 8 cases in group-A and 2 cases in group-B, severe itching in one case in group-A and increasing wound secretion in another case in group-A (P = 0.014).Conclusions:Given the result of the present study, there is no significant difference in cure rates of lesions between yarrow and placebo topical gels as an adjuvant drugs with intralesional glucantime in treatment of acute cutaneous leishmanial lesions.

show abstract

Topical Amphotericin B for Cutaneous Leishmaniasis

Cited by 26 publications

References 2 publications

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis

American cutaneous leishmaniasis in infancy and childhood

The efficacy of Achilles millefolium topical gel along with intralesional injection of glucantime in the treatment of acute cutaneous leishmaniasis major

Contact Info

Product

Resources

About